SCHEMBL12846265

SCHEMBL12846265

CNC(=O)CNC(=O)c1ccc(C2=NOC(c3cc(Cl)cc(Cl)c3)(C(F)(F)F)C2)cc1C

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.38
KDM4E B2RXH2 1/20 0.33
VEGFA P15692 1/20 0.33
FLT1 P17948 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
EGLN3 Q9H6Z9 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
MRGPRX4 Q96LA9 1/20 0.32
ELOVL6 Q9H5J4 1/20 0.31
PDK2 Q15119 1/20 0.31
KMT2A Q03164 2/20 0.31
CYP3A4 P08684 1/20 0.31
CCR2 P41597 1/20 0.31
ORAI1 Q96D31 2/20 0.30
ALDH1A1 P00352 1/20 0.30
MEN1 O00255 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18773293 0.96 HDAC4 (0.36) HDAC4KDM4EVEGFAFLT1EGLN1
SCHEMBL12846262 0.93 TTK (0.33) HDAC4KDM4ECA1CA2ELOVL6
Fluralaner SCHEMBL8515337 0.92 CA1 (0.32) HDAC4KDM4ECA1CA2ELOVL6
Fluralaner SCHEMBL29362559 0.92 CA1 (0.32) HDAC4KDM4ECA1CA2ELOVL6
Fluralaner SCHEMBL121934 0.92 CA1 (0.32) HDAC4KDM4ECA1CA2ELOVL6
Fluralaner SCHEMBL29399660 0.92 CA1 (0.32) HDAC4KDM4ECA1CA2ELOVL6
Fluralaner SCHEMBL8513367 0.92 CA1 (0.32) HDAC4KDM4ECA1CA2ELOVL6
SCHEMBL737408 0.92 EGLN1 (0.36) KDM4EVEGFAFLT1EGLN1EGLN3
SCHEMBL740369 0.92 CA1 (0.34) KDM4ECA1CA2ELOVL6KMT2A
SCHEMBL23344168 0.92 GPR139 (0.34) HDAC4CA1CA2CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239759-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS INTERVET INC. (US) 2024-07-18 US disclosed
EP-3473101-B1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS FOR FELINES INTERVET INT BV (NL) 2021-05-12 EP disclosed
US-20210061775-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS INTERVET INC. (US) 2021-03-04 US disclosed
EP-3473101-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS FOR FELINES Intervet International B.V. (NL) 2019-04-24 EP disclosed
US-20180155301-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS INTERVET INC. (US) 2018-06-07 US disclosed
US-20160332975-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS INTERVET INC. (US) 2016-11-17 US disclosed
US-20150111936-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS INTERVET INC (US) 2015-04-23 US disclosed
EP-2545777-A1 Isoxazoline compositions and their use as antiparasitics Intervet International B.V. (NL) 2013-01-16 EP disclosed
US-20110059988-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS INTERVET INTERNATIONAL B.V. 2011-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332975-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS PRDX5, TUBA3C, TUBA1C HDAC4 504/4885KDM4E 1217/4885VEGFA 4831/4885
US-20210061775-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS PRDX5, TUBA3C, TUBA1C HDAC4 504/4885KDM4E 1217/4885VEGFA 4831/4885
US-20180155301-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS PRDX5, TUBA3C, TUBA1C HDAC4 504/4885KDM4E 1217/4885VEGFA 4831/4885
US-20150111936-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS PRDX5, TUBA3C, EPX HDAC4 459/4885KDM4E 1249/4885VEGFA 4833/4885
US-20240239759-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS PRDX5, TUBA3C, TUBA1C HDAC4 504/4885KDM4E 1217/4885VEGFA 4831/4885
US-20110059988-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS PRDX5, TUBA3C, AADAC HDAC4 411/4885KDM4E 1064/4885VEGFA 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.